• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Palmaz taps new CEO

Palmaz taps new CEO

September 24, 2015 By Brad Perriello

Palmaz Scientific

Palmaz Scientific said today that it named medtech veteran Dr. Philippe Henri Marco to replace Steven Solomon as president and CEO, after Solomon left last month “to pursue other opportunities.”

Marco, a general partner at Chansu Consulting, was COO at CV Ingenuity until its 2013 acquisition by Covidien. His resume includes stints as VP of clinical, regulatory affairs & quality assurance at Xtent, director of clinical & regulatory affairs at Abbott Vascular and senior clinical marketing manager at Perclose.

Founded in 2008 by coronary stent pioneer Dr. Julio Palmaz, the Fremont, Calif.-based company is working on a coronary stent  based on a “super alloy” it’s developing. Julio Palmaz called Marco ” a perfect fit” for the company.

“His interventional cardiac and endovascular medical industry background is right in line with our company vision of creating a technology platform with the promise to bring to market a revolutionary generation of stents and other implantable devices that could change the practice of medicine. He has an excellent track record in taking medical devices through regulatory approvals to market,” Palmaz said in prepared remarks. “In the past 15 months, under Philippe’s guidance, Chansu Consulting achieved a full FDA IDE (Investigational Device Exemption) approval, two CE marks and a First-in-Human study approval, as well as submitting a PMA (Pre-Market Approval) and two 510k (Pre-Market Notification) filings with the Food & Drug Administration. That sort of experience is vital for Palmaz Scientific at this stage in our development.”

“This company has an extraordinary opportunity to fundamentally change the way medical device development is approached and I am excited to come in at this stage and to have the opportunity to work side by side with Dr. Julio Palmaz, who is one of the truly great innovators in medical history,” Marco added. “We will take the offensive, by designing, testing and producing our own devices, breaking through the current conventional approach to medical device manufacturing. For example, we believe that we can create superior devices to those currently marketed in order to treat patients with peripheral artery disease, intra-cranial aneurysms or structural heart disease, addressing substantial unmet medical needs for both patients and clinicians.”

Saying it was out of cash, Palmaz Scientific had planned last month for Palmaz to step down as chairman, replaced by former Kinetic Concepts Inc. CEO Cathy Burzik (now an operating partner at venture capital shop Targeted Technology). But a day later Burzik abruptly backed out and a planned investment by Targeted Technology was scrapped.

Filed Under: Legal News, Stents Tagged With: Palmaz Scientific, Personnel Moves

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy